Phase 2 Clinical Trials
Mid-stage trials that test whether a drug actually works (efficacy) and at what dose, in a few dozen to a few hundred patients.
October 202646
carmustine, etoposide, cytarabine, melphalan Phase 2 Est. Readout
Pooled allogeneic fecal microbiotherapy Phase 2 Est. Readout
November 202653
cemiplimab Phase 2 Est. Readout
Bedaquiline, pretomanid and TBD09 Phase 2 Est. Readout
Mometasone furoate nasal spray (MFNS) Phase 2 Est. Readout
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks Phase 2 Est. Readout
Enekinragene Inzadenovec (PCRX-201) Phase 2 Est. Readout
SHR-A1811 combined with Pyrotinib. Phase 2 Est. Readout
Bupivacaine Liposome Injection Phase 2 Est. Readout
Cannabisextrakt Avextra 10/10 Lösung Phase 2 Est. Readout
MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) Phase 2 Est. Readout
About Phase 2 Clinical Trials
Phase 2 clinical trials are mid-stage studies — usually dozens to a few hundred patients — designed to establish proof of concept: does the drug produce a clinical effect, at what dose, and with what side-effect profile? They bridge the safety-focused Phase 1 and the confirmatory Phase 3.
Because Phase 2 is the first real test of efficacy in patients with the target disease, its readouts are often the highest-information catalyst in a young company’s life — the moment the market first learns whether the science translates.
Why Phase 2 Trials matter to investors
Phase 2 is statistically the hardest hurdle in drug development — more programs fail here than at any other stage. A clean Phase 2 readout can transform a micro-cap’s valuation and attract partners; a miss frequently ends the program. That asymmetry makes Phase 2 dates a core watch-list catalyst.
Frequently asked questions
What is a Phase 2 clinical trial?
A Phase 2 trial is a mid-stage study in dozens to a few hundred patients that tests whether a drug is effective and identifies the right dose, after Phase 1 established basic safety.
Why are Phase 2 results so important?
Phase 2 is the first genuine test of efficacy in the target disease and has the highest failure rate of any phase, so its readout carries the most new information for investors.
What comes after a successful Phase 2 trial?
Positive Phase 2 data typically leads to an end-of-Phase-2 meeting with the FDA and the design of pivotal Phase 3 trials — and often a financing or partnership.